ArticleClinical oral investigations2025
Development of citral-based hydrogel for the treatment of oral candidosis: in vitro and in vivo study.
Article in Clinical oral investigations, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOral candidosis is very common and fungi resistance to drugs available on the market has been reported, as well as a high rate of recurrences. New treatment alternatives are studied.
objectiveThis study developed a citral-based hydrogel (CBH), performed the physical-chemical characterization and evaluated, in vitro, the microbial susceptibility to Candida spp. and the growth kinetics. It also analyzed acute in vivo toxicity and mutagenicity through the micronucleus test in mouse erythrocytes. MATERIALS AND
methodsThe following strains were used in the antifungal activity assays: C. albicans ATCC 10,231, C. glabrata ATCC 90,030, C. krusei ATCC 6258, C. tropicalis ATCC 750, C. parapsilosis ATCC 22,019 and clinical strains of C. albicans A4, C. albicans A5 and C. albicans A6. Microbial susceptibility was verified by the agar disk diffusion test and the effect on the growth kinetics of C. albicans (ATCC 10231). Acute toxicity and clastogenic and aneugenic potential were evaluated in Mus Musculus mice, line Swiss, age six weeks (CBH 2000 mg/kg). Data were analyzed by descriptive and inferential ANOVA and Tukey statistics.
resultsCBH showed inhibition halos greater than or equal to 10 mm in diameter depending on the concentration analyzed, for all Candida strains tested. The product significantly inhibited the growth of C. albicans ATCC 10,231 at all different inoculum concentrations evaluated, between 15 and 120 min, when compared to the growth control. CBH did not induce signs of acute toxicity in mice submitted to gavage treatment at a single dose of 2000 mg/kg. CBH produced a statistically significant smaller number of micronuclei compared to the positive control (cyclophosphomide 50 mg/kg) in erythrocytes from mice.
conclusionThe citral-based hydrogel proved to be a potential antifungal agent against Candida species, with low toxicity and mutagenicity.
Indexed as
Identifiers
41114858What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.